GENERAL ASSEMBLY OF NORTH CAROLINA
HOUSE BILL 821
Short Title: Proper Administration of Step Therapy.
Representatives Lewis and Wray (Primary Sponsors).
For a complete list of Sponsors, refer to the North Carolina General Assembly Web Site.
April 15, 2015
A BILL TO BE ENTITLED
AN ACT to ensure the proper administration of step therapy protocols for prescription drugs.
Whereas, health benefit plans are increasingly making use of step therapy protocols under which patients are required to try one or more prescription drugs before coverage is provided for a drug selected by the patient's health care provider; and
Whereas, when step therapy protocols are based on well‑developed scientific standards and administered in a flexible manner that takes into account the individual needs of patients, the protocols can play an important role in controlling health care costs; and
Whereas, in some cases, requiring a patient to follow a step therapy protocol may have adverse and even dangerous consequences for the patient who may either not realize a benefit from taking a prescription drug or may suffer harm from taking an inappropriate drug; and
Whereas, without uniform policies in the State for step therapy protocols, patients may not receive the best and most appropriate treatment; and
Whereas, it is imperative that step therapy protocols preserve the heath care provider's right to make treatment decisions in the best interest of the patient; and
Whereas, the General Assembly declares it a matter of public interest that it require health benefit plans base step therapy protocols on appropriate clinical practice guidelines developed by independent experts with knowledge of the condition or conditions under consideration; that patients be exempt from step therapy protocols when inappropriate or otherwise not in the best interest of the patients; and that patients have access to a fair, transparent, and independent process for requesting an exception to a step therapy protocol when appropriate; Now, therefore,
The General Assembly of North Carolina enacts:
SECTION 1. Article 50 of Chapter 58 of the General Statutes is amended by adding a new Part to read:
"Part 8. Administration of Step Therapy Protocols.
"§ 58‑50‑300. Definitions.
Unless the context clearly indicates otherwise, the following words or phrases, as used in this Article, have the following meanings:
(1) "Clinical practice guidelines" means a systematically developed statement to assist health care provider and patient decisions about appropriate health care for specific clinical circumstances and conditions.
(2) "Clinical review criteria" means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by an insurer, health plan, or utilization review organization to determine the medical necessity and appropriateness of health care services.
(3) "Step therapy override determination" means a determination as to whether a step therapy protocol should apply in a particular situation, or whether the step therapy protocol should be overridden in favor of immediate coverage of the health care provider's selected prescription drug. This determination is based on a review of the patient's or prescriber's request for an override, along with supporting rationale and documentation.
(4) "Step therapy protocol" means a protocol or program that establishes the specific sequence in which prescription drugs for a specified medical condition are medically appropriate for a particular patient and are covered by an insurer or health plan.
(5) "Utilization review organization" as defined in G.S. 59‑50‑61(a)(18).
"§ 58‑50‑305. Clinical review criteria.
Clinical review criteria used to establish a step therapy protocol shall be based on clinical practice guidelines that meet all the following requirements:
(1) Recommend that the prescription drugs be taken in the specific sequence required by the step therapy protocol.
(2) Are developed and endorsed by an independent, multidisciplinary panel of experts not affiliated with a health benefit plan or utilization review organization.
(3) Are based on high quality studies, research, and medical practice.
(4) Are created by an explicit and transparent process that:
a. Minimizes biases and conflicts of interest;
b. Explains the relationship between treatment options and outcomes;
c. Rates the quality of the evidence supporting recommendations; and
d. Considers relevant patient subgroups and preferences.
(5) Are continually updated through a review of new evidence and research.
"§ 58‑50‑310. Exceptions process transparency.
(a) Exceptions Process. – When coverage of a prescription drug for the treatment of any medical condition is restricted for use by a health benefit plan or utilization review organization through the use of a step therapy protocol, the patient and prescribing practitioner shall have access to a clear and convenient process to request a Step Therapy Exception Determination. A health benefit plan or utilization review organization may use its existing medical exceptions process to satisfy this requirement. The process shall be made easily accessible on the health benefit plan's or utilization review organization's Web site.
(b) Exceptions. – A step therapy override determination request shall be expeditiously granted if any of the following apply:
(1) The required prescription drug is contraindicated or will likely cause an adverse reaction or physical or mental harm to the patient.
(2) The required prescription drug is expected to be ineffective based on the known relevant physical or mental characteristics of the patient and the known characteristics of the prescription drug regimen.
(3) The patient has tried the required prescription drug while under their current or a previous health insurance or health benefit plan or another prescription drug in the same pharmacologic class or with the same mechanism of action and such prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.
(4) The required prescription drug is not in the best interest of the patient, based on medical appropriateness.
(5) The patient is stable on a prescription drug selected by their health care provider for the medical condition under consideration.
(c) Effect of Exception. – Upon the granting of a step therapy override determination, the health benefit plan or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient's treating health care provider, provided such prescription drug is a covered prescription drug under such policy or contract.
(d) Limitations. – This section shall not be construed to prevent:
(1) A health benefit plan or utilization review organization from requiring a patient to try an AB‑rated generic equivalent prior to providing coverage for the equivalent branded prescription drug; or
(2) A health care provider from prescribing a prescription drug that is determined to be medically appropriate.
"§ 58‑50‑315. Rules.
The Commissioner shall adopt rules to implement this Article."
SECTION 2. This act becomes effective October 1, 2015, and applies to health benefit contracts issued, renewed, or amended on or after that date.